Polypharmacy of osteoarthritis: the perfect intestinal storm (Q38124006)

29 August 2017

Polypharmacy of osteoarthritis: the perfect intestinal storm (English)

1 reference

29 August 2017

0 references

John L Wallace

1

1 reference

29 August 2017

25 July 2013

1 reference

Digestive Diseases and Sciences

29 August 2017

1 reference

29 August 2017

58

1 reference

29 August 2017

3088-3093

1 reference

29 August 2017

11

1 reference

https://scigraph.springernature.com/pub.10.1007/s10620-013-2777-8

29 August 2017

0 references

cites work

Epidemiology of osteoarthritis.

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2777-8

American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2777-8

Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2777-8

Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2777-8

Exacerbation of nonsteroidal anti-inflammatory drug-induced small intestinal lesions by antisecretory drugs in rats: the role of intestinal motility.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2777-8

Is non-steroidal anti-inflammaory drug (NSAID) enteropathy clinically more important than NSAID gastropathy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2777-8

Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2777-8

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2777-8

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2777-8

Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2777-8

Selective COX-2 inhibitors: is the water becoming muddy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2777-8

Interactions between Helicobacter pylori and other risk factors for peptic ulcer bleeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2777-8

Drug Resistance and Pseudoresistance: An Unintended Consequence of Enteric Coating Aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2777-8

Prostaglandins, NSAIDs, and Gastric Mucosal Protection: Why Doesn't the Stomach Digest Itself?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2777-8

NSAID gastropathy and enteropathy: distinct pathogenesis likely necessitates distinct prevention strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2777-8

Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2777-8

Effect of omeprazole on intragastric bacterial counts, nitrates, nitrites, and N-nitroso compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2777-8

Review article: proton pump inhibitors and bacterial overgrowth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2777-8

Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2777-8

Effects of long-term PPI treatment on producing bowel symptoms and SIBO.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2777-8

Proton pump inhibitors are associated with elevation of faecal calprotectin and may affect specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2777-8

Considerations for the use of proton-pump inhibitors in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2777-8

Microscopic colitis associated with omeprazole and esomeprazole exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2777-8

Proton pump inhibitor use is associated with an increased risk for microscopic colitis: a case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2777-8

Association between proton pump inhibitor use and anemia: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2777-8

Risk factors for severe nonsteroidal anti-inflammatory drug-induced small intestinal damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2777-8

Role of intestinal bacteria in ileal ulcer formation in rats treated with a nonsteroidal antiinflammatory drug.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2777-8

Probiotic Lactobacillus casei strain Shirota prevents indomethacin-induced small intestinal injury: involvement of lactic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-013-2777-8

Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis

21 January 2018

1 reference

12 December 2020

Aging, the gastrointestinal tract, and risk of acid-related disease

1 reference

12 December 2020

Culture supernatants of Lactobacillus acidophilus and Bifidobacterium adolescentis repress ileal ulcer formation in rats treated with a nonsteroidal antiinflammatory drug by suppressing unbalanced growth of aerobic bacteria and lipid peroxidation

1 reference

12 December 2020

Lower GI bleeding is more common than upper among patients on dual antiplatelet therapy: long-term follow-up of a cohort of patients commonly using PPI co-therapy

1 reference

12 December 2020

Objective evidence of aspirin use in both ulcer and nonulcer upper and lower gastrointestinal bleeding

1 reference

12 December 2020

Sustained release and enteric coated NSAIDs: are they really GI safe?

1 reference

12 December 2020

The pathogenesis and consequence of non steroidal anti-inflammatory drug induced small intestinal inflammation in man.

1 reference

12 December 2020

Long-term effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective agents on the small bowel: a cross-sectional capsule enteroscopy study

1 reference

12 December 2020

Faecal calprotectin: a biomarker of gastrointestinal disease in systemic sclerosis

1 reference

12 December 2020

Factors predicting the presence of small bowel lesions in patients with obscure gastrointestinal bleeding

1 reference

12 December 2020

A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group

1 reference

12 December 2020

GI bleeding: problems that persist

1 reference

12 December 2020

Differences in the severity of small bowel mucosal injury based on the type of aspirin as evaluated by capsule endoscopy

1 reference

12 December 2020

Cardioprotective effects and gastrointestinal risks of aspirin: maintaining the delicate balance

1 reference

12 December 2020

1 reference

12 December 2020

10.1007/S10620-013-2777-8

Identifiers

DOI

1 reference

PubMed ID

23884755

Dimensions Publication ID

29 August 2017

0 references

1 reference

PubMed ID

23884755